
The deadly drug that's complicating US-China trade
The fentanyl crisis is the 'US's problem,' Chinese officials have repeatedly said, and China has already done 'tremendous work' to address the issue.
'We stand ready for practical cooperation with the US based on equality and mutual respect. That said, we firmly oppose the US pressuring, threatening and blackmailing China under the pretext of the fentanyl issue,' a spokesperson said in March, after Trump's fentanyl tariffs were raised to 20% on all Chinese imports into the US.
But as those tariffs remain in place months later and, despite a truce de-escalating other duties, Beijing is signaling it's paying attention to the issue – and may be prepared to do more.
China late last month announced it will add two more fentanyl precursors to its list of controlled substances – an expected step that brought it in line with international regulations, which its diplomats presented as a mark of 'active participation' in global drug control.
Days earlier, Chinese authorities also extended control over another class of drug known as nitazenes – powerful synthetic opioids raising alarm among global health officials. The same day, Chinese Minister of Public Security Wang Xiaohong told US Ambassador to China David Perdue that Beijing was open to strengthening 'practical cooperation' on drug control.
The Trump administration blames China for 'sustaining' the influx into the US of fentanyl, a lab-made, synthetic opioid dozens of times more potent than heroin. Abuse of the drug and its analogues has fueled a drug overdose crisis in the US, killing tens of thousands of Americans annually, though those numbers saw a significant drop last year.
In Beijing's view, it's gone above and beyond international norms to stem the outflow of the drug and its component chemicals from its vast pharmaceuticals sector. In 2019 Beijing controlled fentanyl as a drug class – a significant move that drastically reduced the flow of the finished drug directly from China to the US, according to experts and US officials.
It didn't take long for criminal networks to adapt, however. Chinese outfits shifted to selling precursor chemicals often to cartel-backed labs in Mexico, which then make and ship illegal fentanyl and similar drugs to the US. Chinese authorities have since controlled a number of these precursor chemicals. But experts and US officials say more could be done – as Beijing remains the largest source for products used to make illegal fentanyl and other synthetic drugs in Mexico and other countries.
Chinese officials haven't explicitly linked their recent efforts at controlling two more of these substances to relations with the US, instead calling them another example of the 'goodwill China has shown,' and continuing to reject the premise of the US tariffs.
But Beijing is likely expecting it will get credit for the latest moves in trade negotiations with the US. The question, however, is whether the steps will move the needle for Washington – and whether the two sides will be able to cooperate on the issue if their overall relations remain rocky.
'If Washington does not publicly recognize Chinese steps and show responsiveness to Beijing's own concerns, then bilateral law enforcement cooperation likely will falter going forward,' said Ryan Hass, director of the John L. Thornton China Center at the Brookings Institution.
As US-China ties have chafed on everything from technology to China's militarization of the South China Sea, few issues have appeared more personal to American leaders than China's role as a producer of the drugs and chemicals fueling an opioid crisis in the US.
During his first term, Trump hailed Chinese leader Xi Jinping's 'wonderful humanitarian gesture' of designating fentanyl a controlled substance in China.
Some six years later, however, Trump began his second term accusing China of 'actively sustaining and expanding the business of poisoning our citizens' – an accusation vehemently denied by China.
That message also contrasts with assessments from the US Drug Enforcement Agency which, in an annual report released in May, said fentanyl purity declined throughout 2024, consistent with indications that fentanyl cooks in Mexico were having trouble obtaining key precursor chemicals. That was as some China-based suppliers were 'wary of supplying controlled precursors … demonstrating an awareness on their part that the Chinese government is controlling more fentanyl precursors,' it said.
Beijing's latest moves to control the two additional fentanyl precursors and nitazenes are positive actions that could have an impact on illicit drug supply chains, experts say.
But they are also 'clever maneuvering' from China, according to Vanda Felbab-Brown, a senior fellow at the Strobe Talbott Center for Security, Strategy, and Technology at the Brookings Institution.
A UN convention on illicit drugs added the two fentanyl precursors to its list of controlled substances last year, meaning signatory countries such as China must follow suit. China controlled a number of nitazenes in 2024 and the latest step, which expands those controls, was already in the works last fall, Felbab-Brown said.
'The Trump administration just reset the clock, did not recognize what China had already done and had committed to do, did not give China any credit for that. As a result, it also now is in a position where China can be promising to do exactly the same actions that it had promised to the Biden administration and use that as part of the bargaining,' Felbab-Brown said.
A 'more effective posture' would have been to embrace China's efforts in 2024 and then ask it to fill in the 'substantial and impactful' holes in its drug control program, she added.
Beijing has fiercely defended its record when it comes to controlling fentanyl and other synthetic drugs, releasing a 7,000-word white paper outlining its efforts in March, days after Trump imposed his second raft of fentanyl-linked tariffs.
It has also balked at a Congressional report released last year accusing the ruling Chinese Communist Party of directly subsidizing the manufacture and export of illicit fentanyl materials and other synthetic narcotics through tax rebates.
In China, where the Communist Party keeps a tight grip on all aspects of society, there's comparatively limited opioid abuse, according to official data – a situation Beijing uses to suggest the problem is about American appetite for the drug, not Chinese supply.
That also means Chinese officials feel they've gone out of their way to work with Washington on a US domestic issue – efforts they see as being greeted first by a lack of American appreciation, and then by tariffs.
Scientists in China on the front lines of identifying new precursors being used by criminal groups also point to reducing demand in the US as a key factor, given the challenges of controlling chemicals involved in synthesizing opioids.
'You really can't solve the fentanyl problem through control alone… the most fundamental issue is still reducing demand,' Hua Zhendong, deputy director of a drug analysis division at a counternarcotics laboratory under China's Ministry of Public Security, told CNN in an interview last September.
He pointed to how some chemicals have widespread use in legitimate products, making them impractical to control, while chemicals used to make fentanyl can be easily adjusted to evade rules but still produce the product.
'It's always been like a cat-and-mouse game, because there could be thousands of potential substances for synthesizing fentanyl, we can't proactively control them all – we can only passively follow behind,' said Hua, whose lab was working regularly with US counterparts at the time of the interview to share information on emerging chemicals.
Outside observers agree that US efforts to curb demand are critical for mitigating the opioid crisis. They note too that even if no chemicals came from China, fentanyl makers would look to other countries with large pharmaceuticals and chemicals industries, such as India.
Despite the challenges of enforcement in a vast sector where goods are often shipped in covert ways by busy air and sea routes, observers also say that more can be done in China.
That includes tightening regulations to enable tougher punishments for people who sell controlled precursors to criminal groups or their middlemen unknowingly. Experts also say more could also be done to enforce existing regulations, especially in terms of how central government edicts are enforced by local authorities across China.
'Scheduling drugs and precursors that lead to the production of illegal drugs is one step of many needed in China,' said David Luckey, a senior international and defense researcher at RAND, a US-based think tank. 'I would suggest better still would be actually preventing Chinese companies from selling and distributing these harmful chemicals and drugs to criminal organizations in Mexico.'
In addition to China, Trump placed tariffs on Mexico and Canada earlier this year, accusing them of not doing enough to curb migration and fentanyl trafficking, but carved out significant exemptions to those tariff rates. The US earlier this year designated Mexican cartels it alleges are involved in fentanyl trafficking as foreign terrorist organizations.
'China is a command economy with extreme control of its population – I think if the Chinese Communist Party didn't want Chinese companies doing this, the CCP could do more to stop it, and be more effective in stopping it,' Luckey said.
An annual US State Department report on narcotics controls released in March described China's 'significant steps' working with the US last year to reduce precursor exports, which it said included cracking down on online platforms and companies selling them, making arrests, and adding 55 synthetic drugs and precursor chemicals to control lists.
China's Ministry of Public Security last month said it had seized more than 1,400 tons of various precursor chemicals, and 151 related criminal cases were resolved in 2024.
But authorities in China also acknowledge the scope of the problem, with a recent report noting that channels and means for smuggling chemicals out of the country 'were increasing' and 'constantly being updated,' creating 'greater challenges.'
Beijing – which seeks to present itself as a responsible global player – has its own reasons for not wanting to be seen as an international purveyor of illicit drugs. But Chinese officials have long linked cooperation with the US on the issue to the health of the broader relationship.
China cut off drug control cooperation completely in August 2022 in retaliation for then House Speaker Nancy Pelosi's visit to Taiwan. It then took a friendly summit between Xi and former US President Joe Biden in late 2023 to get collaboration back on track.
This time around, China has bristled at the Trump administration's off-the-bat imposition of tariffs, saying it 'undermines' cooperation. The White House did not respond to a CNN request for comment on China's latest control steps.
'If the US truly wants to cooperate with China, it should face up to the objective facts, correct its wrongdoing, and seek dialogue with China,' a Chinese foreign ministry spokesperson said last month when asked whether those measures were done in cooperation with the US or at its behest.
But Beijing is also keenly aware that the current tariffs are hitting at a time when China's economy has already been struggling with domestic challenges – and there's no certainty those duties couldn't rise again under Trump's capricious trade policy.
'Since the 20% tariff is specifically linked to cooperation on fentanyl, the Chinese might be hoping for a package deal that includes trade, counternarcotics, among other things,' said Yun Sun, director of the China program at the Stimson Center think tank in Washington.
'The Chinese hope to remove the 20% tariff … (and are) eager to get President Trump to visit China this year, so they need to work out good progress,' she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

26 minutes ago
Trump is attending the FIFA Club World Cup final
WASHINGTON -- President Donald Trump on Sunday will attend the FIFA Club World Cup final, a match that will offer Trump a preview of the globe's premier soccer tournament that North America will host next year. Trump and first lady Melania Trump will travel from their golf club in Bedminster, New Jersey, to East Rutherford 40 miles (64 kilometers) away to watch the final match of the U.S.-hosted tournament between Paris Saint-Germain and Chelsea at MetLife Stadium. Trump's trip Sunday falls on the first anniversary of the assassination attempt he survived in Butler, Pennsylvania, while campaigning for president. The president did not have any public plans to mark the date beyond participating in a taped Fox News Channel interview with his daughter-in-law Lara Trump that aired Saturday night. Sporting events have made up the bulk of Trump's trips in the U.S. since taking office this year. In addition to his visit this weekend to the soccer tournament, he's attended the Super Bowl in New Orleans, the Daytona 500 in Florida, UFC fights in Miami and Newark, New Jersey, and the NCAA wrestling championships in Philadelphia. The president, who has a warm relationship with FIFA President Gianni Infantino, has said he plans to attend multiple matches of the World Cup tournament next year.


Hamilton Spectator
31 minutes ago
- Hamilton Spectator
‘Beautiful' or ‘Ugly,' Trump's big bill shapes the battle for House control in 2026 midterms
WASHINGTON (AP) — Debate over President Donald Trump's sweeping budget-and-policy package is over on Capitol Hill. Now the argument goes national. From the Central Valley of California to Midwestern battlegrounds and suburban districts of the northeast, the new law already is shaping the 2026 midterm battle for control of the House of Representatives. The outcome will set the tone for Trump's final two years in the Oval Office. Democrats need a net gain of three House seats to break the GOP's chokehold on Washington and reestablish a power center to counter Trump. There's added pressure to flip the House given that midterm Senate contests are concentrated in Republican-leaning states, making it harder for Democrats to reclaim that chamber. As Republicans see it, they've now delivered broad tax cuts, an unprecedented investment in immigration enforcement and new restraints on social safety net programs. Democrats see a law that rolls back health insurance access and raises costs for middle-class Americans while cutting taxes mostly for the rich, curtailing green energy initiatives and restricting some workers' organizing rights. 'It represents the broken promise they made to the American people,' said Rep. Suzan DelBene, a Washington Democrat who chairs the party's House campaign arm. 'We're going to continue to hold Republicans accountable for this vote.' Parties gear up for a fight Whether voters see it that way will be determined on a district-by-district level, but the battle will be more intense in some places than others. Among the 435 House districts, only 69 contests were decided by less than 10 percentage points in the 2024 general election. The Democratic Congressional Campaign Committee has so far identified 26 Democratic-held seats it must defend vigorously, along with 34 GOP-held seats it believes could be ripe to flip. Republicans' campaign arm, the National Republican Congressional Committee, has so far listed 18 GOP incumbents as priorities, plus two districts opened by retirements. There are a historically low number of so-called crossover districts: Only 13 Democrats represent districts Trump carried in 2024, while just three Republicans serve districts Democratic presidential nominee Kamala Harris carried. Both committees are busy recruiting challengers and open-seat candidates and more retirements could come, so the competitive map will evolve. Still, there are clusters of districts guaranteed to influence the national result. California, despite its clear lean to Democrats statewide, has at least nine House districts expected to be up for grabs: three in the Central Valley and six in southern California. Six are held by Democrats, three by the GOP. Pennsylvania features four districts that have been among the closest national House races for several consecutive cycles. They include a suburban Philadelphia seat represented by Rep. Brian Fitzpatrick, one of just two House Republicans to vote against Trump's bill and one of the three GOP lawmakers from a district Harris won. Fitzpatrick cited the Medicaid cuts. Vice President JD Vance plans on Wednesday to be in Republican Rep. Rob Bresnahan's northwest Pennsylvania district to tout the GOP package. Bresnahan's seat is a top Democratic target. Iowa and Wisconsin, meanwhile, feature four contiguous GOP-held districts in farm-heavy regions where voters could be swayed by fallout from Trump's tariffs. Democrats fight to define the GOP Beyond bumper-sticker labels – Trump's preferred 'Big Beautiful Bill' versus Democrats' 'Big Ugly Bill' retort – the 900-page law is, in fact, an array of policies with varying impact. Democrats hammer Medicaid and food assistance cuts, some timed to take full effect only after the 2026 midterms, along with Republicans' refusal to extend tax credits to some people who obtained health insurance through the Affordable Care Act. The Congressional Budget Office estimates that 11.8 million more Americans would become uninsured by 2034 if the bill became law; 3 million more would not qualify for food stamps, also known as SNAP benefits. 'Folks will die here in Louisiana and in other parts of the country,' House Minority Leader Jeffries warned last week during a town hall in Republican Speaker Mike Johnson's home state of Louisiana. Jeffries singled out vulnerable Republicans like California Rep. David Valadao, who represents a heavily agricultural Central Valley district where more than half the population is eligible for the joint state-federal insurance program. California allows immigrants with legal status and those who are undocumented to qualify for Medicaid, so not all Medicaid recipients are voters. But the program helps finance the overall health care system, including nursing homes and hospitals. Republicans highlight the law's tightened work requirements for Medicaid enrollees. They argue it's a popular provision that will strengthen the program. 'I voted for this bill because it does preserve the Medicaid program for its intended recipients — children, pregnant women, the disabled, and elderly,' Valadao said. 'I know how important the program is for my constituents.' Republicans hope voter s see lower taxes The law includes $4.5 trillion in tax cuts. It makes permanent existing rates and brackets approved during Trump's first term. Republicans and their allies have hammered vulnerable Democrats for 'raising costs' on American households by opposing the bill. GOP campaign aides point to the popularity of individual provisions: boosting the $2,000 child tax credit to $2,200 (some families at lower income levels would not get the full credit), new deductions on tip and overtime income and auto loans; and a new deduction for older adults earning less than $75,000 a year. 'Everyone will have more take home pay. They'll have more jobs and opportunity,' Johnson said in a Fox News Sunday interview. 'The economy will be doing better and we'll be able to point to that as the obvious result of what we did.' Democrats note that the biggest beneficiaries of Trump's tax code are wealthy Americans and corporations. Pairing that with safety net cuts, Florida Rep. Debbie Wasserman Schultz concluded, 'The cruelty is the point.' Immigration, meanwhile, was Trump's strongest issue in 2024. NRCC aides say that will continue with the new law's investments in immigration enforcement. Democrats believe the Trump administration has overplayed its hand with its push for mass deportation. Playing the Trump card The president is a titanic variable. Democrats point to 2018, when they notched a 40-seat net gain in House seats to take control away from the GOP. This year, Democrats have enjoyed a double-digit swing in special elections around the country when compared to 2024 presidential results. Similar trends emerged in 2017 after Trump's 2016 victory. Democrats say that reflects voter discontent with Trump once he's actually in charge. Republicans answer that Trump's job approval remains higher at this point than in 2017. But the GOP's effort is further complicated by ongoing realignments: Since Trump's emergence, Democrats have gained affluent white voters -– like those in suburban swing districts -– while Trump has drawn more working-class voters across racial and ethnic groups. But Republicans face a stiffer challenge of replicating Trump's coalition in a midterm election without him on the ballot. Democrats, meanwhile, must corral voters who are not a threat to vote for Republicans but could stay home. Jeffries said he's determined not to let that happen. 'We're going to do everything we can until we end this national nightmare.' —- Cooper reported from Phoenix. Brook reported from New Orleans. Associated Press reporters Michael Blood in Los Angeles and Marc Levy in Harrisburg, Pennsylvania, contributed. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .


Washington Post
36 minutes ago
- Washington Post
'Beautiful' or 'Ugly,' Trump's big bill shapes the battle for House control in 2026 midterms
WASHINGTON — Debate over President Donald Trump's sweeping budget-and-policy package is over on Capitol Hill. Now the argument goes national. From the Central Valley of California to Midwestern battlegrounds and suburban districts of the northeast, the new law already is shaping the 2026 midterm battle for control of the House of Representatives. The outcome will set the tone for Trump's final two years in the Oval Office.